LONDON (Reuters) ? Daniel Craig will be back dodging bullets and vanquishing villains from China to Turkey in the 23rd installment of the James Bond film franchise, but the stars and director of "Skyfall" are keeping the who, what and how under wraps for now.
As previously announced, Oscar-winning director Sam Mendes directs his first Bond adventure, which celebrates its 50th anniversary in 2012 when Skyfall is released.
One of the few details Mendes revealed to more than 100 reporters from around the world at the film's London press launch were his cast and the locations of the blockbuster, which starts production on Monday.
Bond regulars Craig and Judi Dench, as his stern spymaster M, return to their roles, Spanish actor Javier Bardem plays the villain and French actress Berenice Marlohe and Britain's Naomie Harris are Bond girls.
All five were at the press briefing, where they were joined by Bond producers Barbara Broccoli and Michael Wilson.
In addition, Mendes said the latest installment in one of cinema's longest and most successful film franchises will feature Ben Whishaw "who will be playing a part I can't tell you about in scenes I can tell you nothing about.
"And Albert Finney, who will also be playing a part I can tell you nothing about in scenes that I can't really tell you about and Ralph Fiennes, who, similarly, I can give you very little information about."
Asked whether he had not named all of the characters the leading actors would be playing because Bond fans might recognize them, the "American Beauty" director replied: "They might do. On the other hand they might not."
What producers have confirmed is that Skyfall will take Bond on another action-packed mission to London, Shanghai, Istanbul and Scotland.
A press release gave a brief plot outline, saying Bond's loyalty to M is tested "as her past comes back to haunt her.
"As MI6 (British intelligence) comes under attack, 007 must track down and destroy the threat, no matter how personal the cost."
NO "AUSTERITY" BOND
Mendes and his producers sought to reassure fans that tough economic conditions in the real world would not make the fictional exploits of the suave superspy any less spectacular.
"It, I think, has all the elements of a classic Bond movie, including, to quell any rumors, a lot of action," Mendes said.
Wilson added: "I think it's in the same (cost) range as the last film and we really haven't had to change anything in the script. We haven't had to sacrifice anything."
The 22nd Bond movie, "Quantum of Solace," cost an estimated $200 million to produce, more than the previous installment and Craig's Bond debut "Casino Royale," which cost a reported $150 million.
Any extra outlay did not translate into higher ticket sales, however, with Casino Royale earning $594 million at the global box office and Quantum of Solace $586 million, according to website www.boxofficemojo.com.
Sony Pictures, part of Sony Corp, will distribute Skyfall, which is set to hit British theaters on October 26, 2012 and U.S. cinemas on November 9 after a studio bankruptcy put production on hold for months and the last movie earned mixed reviews.
Next year is the 50th anniversary of the series, which began in 1962 with Sean Connery -- breathing life into the character created by former intelligence officer and novelist Ian Fleming -- on Her Majesty's secret service in "Dr. No."
Debt-laden Metro-Goldwyn-Mayer Studios Inc, known for its roaring lion logo and behind some of Hollywood's most fabled films including "The Wizard of Oz," filed for bankruptcy in November last year.
But two months later it confirmed Bond 23 would hit theatres in November, 2012, and in April MGM and Sony announced they would co-finance and distribute the next two Bond movies.
Craig's first appearance as Bond in 2006 was hailed as a refreshing change in direction toward a tougher, more serious 007, and reviews were overwhelmingly positive.
Quantum of Solace fared less well with the critics, although positive reviews still outweighed the negative and both films were commercially successful.
When Craig was asked if he would continue in one of cinema's most recognizable roles for a few more years, Broccoli interjected and said: "Yes, definitely."
NEW YORK ? Insurer AIG has posted a steeper third-quarter loss as declining interest rates and weak stock markets reduced the value of its holdings while it paid out storm losses.
American International Group Inc. reported on Thursday a loss of $4.1 billion, or $2.16 per share, compared with a loss of $2.52 billion, or $18.53 per share a year ago.
The operating loss was $3.04 billion, or $1.60 per share, up from a loss of $114 million, or 84 cents a year ago.
Analysts surveyed by FactSet expected a loss of 22 cents per share.
The company has been paying back the billions of dollars the U.S. government provided in the 2008 bailout and now owes roughly $68 billion.
This week waspackedwith news on the mobile front, so it was easy to miss a few stories here and there. Here's some of the other stuff that happened in the wide world of wireless for the week of October 31, 2011:
If you have a Verizon tablet and a strong aversion for Google Maps, try UpNext HD Maps. Released by the carrier this week, it's interactive and offers 3D, and uses quick tabs to help you find restaurants, nightlife, businesses and so on. [Droid-Life]
Motorola Droid RAZR release rumor: how does November 11th, 2011 at 11:11AM sound? [AndroidCentral]
Apparently it's Verizon week, because here's another one from Big Red. This rumor's about the LG Spectrum, which is being regarded as the Revolution 2. It's apparently showing up in some Verizon database, according to screenshots; the images don't really give away a whole lot, other than the fact it appears to have LTE -- not really a shocker for the sequel to the Revolution. [Droid-Life]
The BlackBerry 9790 Bellagio got a bit of hands-on time, and has a bunch of images to prove it. [N4BB]
Let's face it -- not everyone is enamored by the look of the Motorola RAZR. Y'know, the new one. This week, a version of the device with a different design, dubbed the MT917, was spotted en route to China. It has a lot of similar specs inside, but it has rounded corners and includes a TD-SCDMA radio. [Unwired View]
The Google Reader and Google Docs apps on Android have been given refreshes, both of which having been inspired by Ice Cream Sandwich. Head to the Market and check them out. [Droid-Life]
FILE - In this April 10 2011 file photo taken by T-Hawk drone aircraft and released by Tokyo Electric Power Co. (TEPCO), the reactor building of Unit 2, center, of the Fukushima Dai-ichi nuclear power plant is seen in Okuma town, Fukushima Prefecture, northeastern Japan. Officials at the tsunami-damaged Fukushima Dai-ichi nuclear power plant detected a radioactive gas associated with fission Wednesday, Nov. 2, 2011, that could indicate a new problem at one of its reactors. They began injecting boric acid as a precautionary measure. (AP Photo/Tokyo Electric Power Co., File) EDITORIAL USE ONLY
FILE - In this April 10 2011 file photo taken by T-Hawk drone aircraft and released by Tokyo Electric Power Co. (TEPCO), the reactor building of Unit 2, center, of the Fukushima Dai-ichi nuclear power plant is seen in Okuma town, Fukushima Prefecture, northeastern Japan. Officials at the tsunami-damaged Fukushima Dai-ichi nuclear power plant detected a radioactive gas associated with fission Wednesday, Nov. 2, 2011, that could indicate a new problem at one of its reactors. They began injecting boric acid as a precautionary measure. (AP Photo/Tokyo Electric Power Co., File) EDITORIAL USE ONLY
TOKYO (AP) ? Radioactive particles associated with nuclear fission have been detected at Japan's tsunami-damaged atomic power plant, officials said Wednesday, suggesting one of its reactors could have a new problem.
The fresh concerns at the Fukushima Dai-ichi nuclear facility came as a reactor in southern Japan was restarted and brought back online, marking a first since the March 11 disaster created an outcry over the safety of Japan's nuclear power sites.
Utility officials said gas from inside the Fukushima plant's No. 2 reactor indicated the presence of radioactive xenon, which could be the byproduct of unexpected nuclear fission. Boric acid was injected through a cooling pipe as a precaution because it can counteract nuclear reactions.
Tokyo Electric Power Co., or TEPCO, said there was no rise in the reactor's temperature or pressure. The company said the radioactive materials had not reached the point when nuclear reactions are self-sustaining and the detection of the xenon would have no major impact on workers' efforts to keep the reactor cool and stable.
Because the half-life of the isotopes detected is short, the xenon was likely created recently. But officials said the level was so low that further tests would be required to confirm the measurements were not an error.
"We have confirmed that the reactor is stable and we don't believe this will have any impact on our future work," said TEPCO spokesman Osamu Yokokura. He said no radiation leaks outside the plant were detected.
Hiroyuki Imari, a spokesman with the Nuclear Industrial Safety Agency, said the detection of the gas was not believed to indicate a major problem, but its cause was being investigated.
The plant is the site of the worst nuclear disaster since Chernobyl in 1986. A 12-mile (20-kilometer) exclusion zone has been in effect since the earthquake and tsunami crippled the facility northeast of Tokyo, sending three of its reactors into meltdowns, touching off fires and triggering several explosions.
TEPCO had reported significant progress toward stabilizing the facility, saying that it has essentially reached a "cold shutdown," meaning the temperatures at the reactors are constant and controlled.
Even so, a Japanese government panel says it will take at least 30 years to safely decommission the facility.
The Fukushima disaster has severely impacted Japan's nuclear power supply.
Forty-three of Japan's 54 reactors are now suspended for inspections or mechanical troubles and public opposition to restarting them since the disaster has cast doubts on the nation's overall nuclear future.
Before the tsunami, Japan relied on nuclear power for about one-third of its electricity. If power companies cannot win local approval, which is required to restart reactors shut down for glitches or inspections, all of Japan's plants could be offline by next May.
But, in a first since the disaster, a nuclear reactor in southern Japan has resumed operation after a monthlong shutdown for a technical problem. A reactor in Hokkaido, northern Japan, was brought back online in August, but it had not been completely shut down and was out of commercial service only for a regular inspection.
The Kyushu Electric Power Co. says No. 4 reactor at the Genkai nuclear power plant in southern Japan restarted late Tuesday and was generating electricity Wednesday. It automatically shut down Oct. 4 following an abnormality in a steam condenser, but that didn't cause any radiation leaks or injuries.
The reactor will be closed again in January for routine inspections.
___
Associated Press writer Mari Yamaguchi contributed to this report.
Honda isn't the only Japanese car maker active in robotics (with Asimo etc.), Toyota has been active in this area for quite some time, too. Big T showcased a total of four robots yesterday, all with the healthcare and nursing markets in mind. It's not a surprise Japan's biggest car company is focusing on these areas, as its home country has the oldest society in the world (23% of the population are 65 or older). Here are the robots Toyota showed during their press conference in Tokyo.
NIH study examines nicotine as a gateway drugPublic release date: 2-Nov-2011 [ | E-mail | Share ]
Contact: NIDA Press Team media@nida.nih.gov 301-443-6245 NIH/National Institute on Drug Abuse
NIDA-funded research in mice shows that nicotine primes the brain to enhance cocaine's effects
A landmark study in mice identifies a biological mechanism that could help explain how tobacco products could act as gateway drugs, increasing a person's future likelihood of abusing cocaine and perhaps other drugs as well, according to the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. The study is the first to show that nicotine might prime the brain to enhance the behavioral effects of cocaine.
The gateway drug model is based upon epidemiological evidence that most illicit drug users report use of tobacco products or alcohol prior to illicit drug use. This model has generated significant controversy over the years, mostly relating to whether prior drug exposure (to nicotine, alcohol or marijuana) is causally related to later drug use. Before now, studies have not been able to show a biological mechanism by which nicotine exposure could increase vulnerability to illicit drug use.
In the current study, by researchers at Columbia University, New York City, and published in today's Science Translational Medicine, mice exposed to nicotine in their drinking water for at least seven days showed an increased response to cocaine. This priming effect depended on a previously unrecognized effect of nicotine on gene expression, in which nicotine changes the structure of the tightly packaged DNA molecule, reprograms the expression pattern of specific genes, in particular the FosB gene that has been related to addiction, and ultimately alters the behavioral response to cocaine.
To examine whether the results from this study paralleled findings in humans, the researchers reexamined statistics from the 2003 National Epidemiological Study of Alcohol Related Consequences to explore the relationship between onset of nicotine use and degree of cocaine dependence. They found that the rate of cocaine dependence was higher among cocaine users who smoked prior to starting cocaine compared to those who tried cocaine prior to smoking.
These findings in mice suggest that if nicotine has similar effects in humans, effective smoking prevention efforts would not only prevent the negative health consequences associated with smoking but could also decrease the risk of progression and addiction to cocaine and possibly other illicit drug use. In the meantime, this mouse model provides a new mechanism to study the gateway theory from a biological perspective.
"Now that we have a mouse model of the actions of nicotine as a gateway drug this will allow us to explore the molecular mechanisms by which alcohol and marijuana might act as gateway drugs," said Eric Kandel, M.D., of Columbia University Medical Center and a senior author of the study. "In particular, we would be interested in knowing if there is a single, common mechanism for all gateway drugs or if each drug utilizes a distinct mechanism."
###
For more information on nicotine and cocaine, go to http://www.drugabuse.gov/drugpages/nicotine.html and http://www.drugabuse.gov/drugpages/cocaine.html.
The study, and a perspective by NIDA Director Dr. Nora D. Volkow, can be found online at http://stm.sciencemag.org/.
The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world's research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to inform policy and improve practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found on the NIDA home page at http://www.drugabuse.gov. To order publications in English or Spanish, call NIDA's DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or fax or email requests to 240-645-0227 or drugpubs@nida.nih.gov. Online ordering is available at http://drugpubs.drugabuse.gov. NIDA's media guide can be found at http://drugabuse.gov/mediaguide/.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
NIH study examines nicotine as a gateway drugPublic release date: 2-Nov-2011 [ | E-mail | Share ]
Contact: NIDA Press Team media@nida.nih.gov 301-443-6245 NIH/National Institute on Drug Abuse
NIDA-funded research in mice shows that nicotine primes the brain to enhance cocaine's effects
A landmark study in mice identifies a biological mechanism that could help explain how tobacco products could act as gateway drugs, increasing a person's future likelihood of abusing cocaine and perhaps other drugs as well, according to the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. The study is the first to show that nicotine might prime the brain to enhance the behavioral effects of cocaine.
The gateway drug model is based upon epidemiological evidence that most illicit drug users report use of tobacco products or alcohol prior to illicit drug use. This model has generated significant controversy over the years, mostly relating to whether prior drug exposure (to nicotine, alcohol or marijuana) is causally related to later drug use. Before now, studies have not been able to show a biological mechanism by which nicotine exposure could increase vulnerability to illicit drug use.
In the current study, by researchers at Columbia University, New York City, and published in today's Science Translational Medicine, mice exposed to nicotine in their drinking water for at least seven days showed an increased response to cocaine. This priming effect depended on a previously unrecognized effect of nicotine on gene expression, in which nicotine changes the structure of the tightly packaged DNA molecule, reprograms the expression pattern of specific genes, in particular the FosB gene that has been related to addiction, and ultimately alters the behavioral response to cocaine.
To examine whether the results from this study paralleled findings in humans, the researchers reexamined statistics from the 2003 National Epidemiological Study of Alcohol Related Consequences to explore the relationship between onset of nicotine use and degree of cocaine dependence. They found that the rate of cocaine dependence was higher among cocaine users who smoked prior to starting cocaine compared to those who tried cocaine prior to smoking.
These findings in mice suggest that if nicotine has similar effects in humans, effective smoking prevention efforts would not only prevent the negative health consequences associated with smoking but could also decrease the risk of progression and addiction to cocaine and possibly other illicit drug use. In the meantime, this mouse model provides a new mechanism to study the gateway theory from a biological perspective.
"Now that we have a mouse model of the actions of nicotine as a gateway drug this will allow us to explore the molecular mechanisms by which alcohol and marijuana might act as gateway drugs," said Eric Kandel, M.D., of Columbia University Medical Center and a senior author of the study. "In particular, we would be interested in knowing if there is a single, common mechanism for all gateway drugs or if each drug utilizes a distinct mechanism."
###
For more information on nicotine and cocaine, go to http://www.drugabuse.gov/drugpages/nicotine.html and http://www.drugabuse.gov/drugpages/cocaine.html.
The study, and a perspective by NIDA Director Dr. Nora D. Volkow, can be found online at http://stm.sciencemag.org/.
The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world's research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to inform policy and improve practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found on the NIDA home page at http://www.drugabuse.gov. To order publications in English or Spanish, call NIDA's DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or fax or email requests to 240-645-0227 or drugpubs@nida.nih.gov. Online ordering is available at http://drugpubs.drugabuse.gov. NIDA's media guide can be found at http://drugabuse.gov/mediaguide/.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.